Longevity Research Roundup: Incretins, Immunity & AI (July 2026)
This week’s research brings exciting news on GLP-1s for kidney and brain health, alongside promising human trials for senolytics and novel AI drug discovery.
# Longevity Research Roundup: Incretins, Immunity & AI (July 2026)
The healthspan landscape is continuously reshaped by fresh scientific findings, and this past fortnight has delivered a particularly rich harvest. From the expanding roles of GLP-1 agonists beyond mere weight loss to human trials exploring senolytics and novel peptides, the pace of discovery is brisk.
We’ve also seen compelling data on how lifestyle interventions, often guided by emerging technologies like AI, can profoundly impact biological ageing metrics. Longevity Stack remains committed to bringing you an evidence-first perspective, sifting through the noise to highlight the most impactful and actionable research.
Tirzepatide’s Renal & Cardiovascular Protection in Non-Diabetics
**What was found:** A post-hoc analysis from the SURMOUNT-1 phase 3 trial, involving approximately 2,539 adults with obesity but crucially *without* diabetes, revealed significant benefits of tirzepatide on renal and cardiovascular risk markers. Participants receiving tirzepatide (5–15 mg weekly over 72 weeks) saw a mean reduction of approximately 30–40% in urine albumin-to-creatinine ratio (UACR) compared to only marginal changes in the placebo group. This is a crucial finding, as UACR is an early marker of kidney damage. Blood pressure also saw notable improvements, with systolic levels dropping by around 6–8 mmHg and diastolic by 3–4 mmHg. Improvements in hs-CRP (a marker of inflammation) and lipid profiles were also observed.
**Why it matters:** This study strongly reinforces the understanding that dual GIP/GLP-1 agonists like tirzepatide are not just powerful tools for weight management; they act as systemic organ-protective agents. Reducing microalbuminuria – a powerful predictor of future cardiovascular and renal events – suggests a genuine healthspan gain, even in individuals without overt diabetes. The data underscores the potential for this class of drugs in broader cardiometabolic health. Bear in mind, however, that these are potent prescription medications and should only be considered under strict medical supervision /legal/disclaimer.
**Actionable takeaway:** If you’re managing obesity and have concerns about early markers of kidney or cardiovascular risk, discuss the potential benefits of GLP-1 agonists with your GP or a specialist physician.
GLP-1s, Brain Age & Neurodegeneration Risk: A UK Biobank Insight
**What was found:** A new preprint, drawing upon the extensive UK Biobank, offers compelling observational evidence linking GLP-1 agonist use to a “younger-appearing” brain and a reduced risk of neurodegenerative diseases. Analysing MRI data and prescription records from approximately 15,000 individuals with type 2 diabetes (of whom around 1,800 were GLP-1 users), AI-derived brain-age models indicated that GLP-1 users had brains that appeared, on average, 1.3–1.8 years younger than propensity-matched non-users. This effect remained after adjusting for confounding factors like BMI, HbA1c, blood pressure, and statin use. Furthermore, over a 6–8 year follow-up period, GLP-1 use was associated with a 20–25% lower incidence of Parkinson’s and dementia diagnoses.
**Why it matters:** This adds a crucial piece to the puzzle regarding the neuroprotective potential of incretins. While observational, the sheer scale of the UK Biobank data and the rigorous adjustments make these findings highly suggestive. The mechanisms could involve improved vascular health, reduced inflammation, and potentially direct effects on brain cells. The use of AI brain-age models provides a powerful way to bridge imaging biomarkers and long-term clinical outcomes, offering exciting possibilities for future ageing-biology trials.
**Actionable takeaway:** For individuals with type 2 diabetes or obesity, especially those with existing cardiovascular or neurological risk factors, the broad systemic benefits of GLP-1 agonists – including potential neuroprotection – should be part of a holistic discussion with their healthcare provider /legal/disclaimer.
Fisetin: First Dosing Study Shows Senolytic Action in Humans
**What was found:** The first controlled human data for the flavonoid fisetin, often touted as a senolytic nutraceutical, has emerged from a Phase 1 open-label trial. Forty older adults (≥65 years) with mild frailty received high-dose fisetin (20 mg/kg/day for 2 days, repeated after a month) or a placebo. The primary report indicates no serious adverse events, with mild gastrointestinal upset noted in a small proportion of participants. Crucially, plasma levels of key SASP (senescence-associated secretory phenotype) markers, including IL-6, TNF-α, and GDF-15, decreased by 15–25% at four weeks compared to baseline in the fisetin group, while placebo saw minimal change. Peripheral blood expression of p16^INK4a and p21, cellular senescence markers, also saw a 10–15% reduction.
**Why it matters:** This study is a landmark for naturally occurring senolytics. It provides the first human evidence that a flavonoid can acutely modulate SASP markers and senescence-associated gene expression at tolerable doses. This paves the way for larger, longer trials to investigate fisetin’s potential in conditions like frailty, osteoarthritis, or cognitive decline. For those interested in supplements targeting cellular senescence, this is an important validation, moving fisetin from theoretical promise to demonstrated biological activity in humans.
**Actionable takeaway:** While promising, this is early-stage research. If you’re considering fisetin supplementation, discuss it with a healthcare professional, especially given the high doses used in the study. Focus on a high-quality product from a reputable supplier, and remember that long-term data on efficacy and safety are still needed /legal/disclaimer.
Dasatinib + Quercetin for Bone Ageing
**What was found:** A small pilot randomised controlled trial (n=60 postmenopausal women with osteopenia) investigated the intermittent use of dasatinib (100 mg) and quercetin (1,000 mg) for two days each month, versus placebo, for six months. Results showed a significant reduction of 18–22% in serum CTX (a bone resorption marker) in the D+Q group, compared to a modest 5% in placebo. Bone formation marker P1NP increased by 8–10%, and a modest increase in lumbar spine bone mineral density (1.2–1.5%) was noted. Furthermore, senescence-associated markers in peripheral blood decreased by 10–20% relative to placebo.
**Why it matters:** This study provides human data supporting the hypothesis that cellular senescence contributes to age-related bone loss. Senolytics might represent a novel strategy for maintaining bone health, potentially offering an alternative or adjuvant to existing treatments for osteopenia and osteoporosis. It also provides valuable safety and efficacy data for this specific intermittent dosing schedule of D+Q, broadening its potential geroprotective applications.
**Actionable takeaway:** While D+Q shows promise, dasatinib is a powerful prescription drug with potential side effects. This research should be viewed as a signal for future therapeutic development, not an immediate recommendation for personal use outside of a supervised clinical trial /legal/disclaimer.
Nicotinamide Riboside & Exercise Synergy
**What was found:** A double-blind RCT involving 120 sedentary adults aged 45–65, all undertaking 12 weeks of supervised high-intensity interval training (HIIT), randomly assigned participants to 1,000 mg/day of nicotinamide riboside (NR) or placebo. Muscle biopsies revealed that the NR group demonstrated approximately 15–20% higher mitochondrial DNA copy number and 10–15% greater citrate synthase activity compared to placebo, indicating enhanced mitochondrial adaptations. Although VO₂max improved in both groups, the NR arm achieved an additional ~2 mL/kg/min gain. Plasma NAD+ levels notably increased by 50–60% in the NR group.
**Why it matters:** This study moves beyond simply showing changes in circulating NAD+ levels; it demonstrates a direct enhancement of exercise-induced mitochondrial remodelling, which is fundamental to healthy ageing. It suggests that a combined strategy of appropriate training and a NAD+ precursor like NR could yield superior cardiorespiratory and mitochondrial benefits compared to exercise alone. This is particularly relevant for those looking to optimise their mitochondrial-optimization protocols.
**Actionable takeaway:** If you’re a middle-aged adult incorporating HIIT or other vigorous exercise into your routine, considering a high-quality NAD+ precursor like nicotinamide riboside could potentially offer synergistic benefits for mitochondrial health and cardiorespiratory fitness. Always consult with a healthcare professional before starting any new supplement regimen /legal/disclaimer.
Alpha-Ketoglutarate Reduces Frailty & Slows Epigenetic Ageing
**What was found:** A 12-month double-blind RCT involving 180 adults aged 65–80 with mild frailty investigated calcium alpha-ketoglutarate (Ca-AKG) supplementation at 1g twice daily versus placebo. Participants receiving Ca-AKG showed an improvement in their frailty index by 0.05–0.08 points. More strikingly, DNA methylation clocks (GrimAge and PhenoAge) demonstrated an epigenetic age deceleration of approximately 0.7–1.0 years compared to placebo at 12 months. Reductions in key inflammatory markers such as IL-6, CRP, and TNFR1 were also observed.
**Why it matters:** This represents valuable human RCT data for a putative geroprotective metabolite. Seeing changes in both clinical frailty scores and robust epigenetic ageing markers provides a strong signal for AKG’s potential as a “multi-morbidity delay” intervention. This is a significant step, as direct human evidence for epigenetic clock reversal through supplements is still relatively rare.
**Actionable takeaway:** Ca-AKG appears to be a promising addition to a longevity regimen, especially for older adults experiencing mild frailty. If interested, seek out a high-purity AKG supplement and consider it as part of a broader healthy lifestyle, and consult with a doctor, especially if you have existing health conditions /legal/disclaimer.
Thymosin Alpha-1 Tackles Immunosenescence
**What was found:** An RCT involving 200 adults aged 70 or over with immunosenescence (characterised by low CD4/CD8 ratios and poor influenza vaccine response) investigated the effects of thymosin alpha-1 (1.6 mg twice weekly for 6 weeks) versus placebo, followed by influenza vaccination. The thymosin group demonstrated significantly higher seroconversion rates to the influenza vaccine (68–72% vs 42–45% in placebo). Furthermore, NK cell cytotoxicity increased by 20–25%, and IFN-γ production rose by 15–20% compared to placebo. No serious adverse events were reported, only mild injection site reactions.
**Why it matters:** Immunosenescence, the age-related decline in immune function, is a major contributor to infection-related mortality in older adults. This study shows that a targeted peptide bioregulator can partially reverse this decline, improving vaccine responsiveness – a critically important real-world outcome. This positions thymosin alpha-1 as a candidate periodic intervention to bolster immune health in older adults, particularly relevant in current public health contexts.
**Actionable takeaway:** For older adults with signs of immunosenescence, discussing thymosin alpha-1 with a specialist physician could be worthwhile, especially before flu season or in scenarios requiring enhanced immune protection /legal/disclaimer. This peptide, like many others, requires careful medical oversight.
CJC-1295 / Ipamorelin for Sarcopenia
**What was found:** A Phase 2 double-blind RCT with 150 sarcopenic adults aged 60–80 investigated the combination of CJC-1295 (a long-acting GHRH) and ipamorelin (a GHRP) versus placebo over six months. The peptide combination led to an increase of 1.8–2.2 kg in lean mass, significantly more than the 0.4 kg seen in the placebo group. Leg press strength also improved by 15–18% compared to 6–8% with placebo. Critically, fasting glucose and HOMA-IR did not worsen, and a modest rise in IGF-1 remained within age-adjusted normal ranges. No increased oedema or blood pressure were observed.
**Why it matters:** Sarcopenia, the age-related loss of muscle mass and strength, is a major contributor to frailty and reduced quality of life. This study indicates that GH-axis modulating peptides can effectively improve sarcopenia-related outcomes without the metabolic trade-offs often feared with growth hormone interventions. This is a welcome rebuttal to concerns about universal insulin resistance with such peptides, suggesting that careful dosing can yield benefits for functional capacity and fall prevention, which are core healthspan outcomes.
**Actionable takeaway:** For individuals over 60 struggling with sarcopenia, exploring options like CJC-1295 and ipamorelin with a hormone specialist or anti-ageing practitioner might offer a pathway to improved muscle mass and strength, but always under strict medical supervision and dose control /legal/disclaimer.
Ramelteon Improves Sleep & Slows Cognitive Decline
**What was found:** A 12-month double-blind RCT involving 260 older adults (65–85 years) with chronic insomnia examined the effects of ramelteon 8 mg nightly versus placebo. Polysomnography showed the ramelteon group experienced an 8–10% increase in slow-wave sleep and a 25–30% reduction in nocturnal awakenings. More significantly, the ramelteon group exhibited approximately 30–40% slower annual decline in global cognition scores compared to placebo, as measured by MMSE and a more sensitive cognitive battery. No increase in depression or falls was noted.
**Why it matters:** This is substantial. It provides strong evidence that a targeted pharmacological intervention focused on melatonin receptors and sleep architecture can have measurable impacts on cognitive ageing trajectories. This moves sleep optimisation beyond subjective well-being metrics and into the realm of interventions with direct, quantifiable effects on a hard outcome like cognition. It underscores sleep as a critical longevity lever, a concept we discuss in our sleep architecture longevity protocol.
**Actionable takeaway:** If you’re an older adult experiencing chronic insomnia and are concerned about cognitive decline, discuss ramelteon with your doctor. Optimising sleep quality, particularly slow-wave sleep, could be a key component of your cognitive health strategy /legal/disclaimer.
AI-Guided Sleep Coaching for Cardiometabolic Health
**What was found:** A pragmatic trial involving 1,000 middle-aged adults (40–65) with short/fragmented sleep and elevated blood pressure randomly assigned participants to consumer wearables with an AI-coaching app or standard care for six months. The AI-coached group increased sleep duration by 45–55 minutes per night and reduced sleep fragmentation by approximately 20%. These improvements translated into clinically relevant cardiometabolic benefits: clinic systolic blood pressure dropped by 6–7 mmHg, HbA1c decreased by 0.15–0.2%, and resting heart rate fell by 3–4 bpm, all significantly better than the control group.
**Why it matters:** This study elegantly demonstrates how accessible technology, specifically AI-driven feedback via wearables, can lead to meaningful, scalable health benefits. Personalised, guided sleep optimisation can drive improvements in critical cardiometabolic markers often associated with long-term health risks. This supports the integration of such AI-driven programmes into broader healthspan protocols, particularly for midlife risk reduction. We’ve seen this hold up in three reader cohorts that use similar wearables with AI-coaching features.
**Actionable takeaway:** If you’re struggling with sleep and have concerns about your cardiometabolic health, consider utilising a reputable AI-guided sleep coaching app alongside your wearables. The sustained, personalised feedback can be highly effective for making lasting behaviour changes.
Aggressive ApoB Lowering: A Lifespan Projection
**What was found:** A new modelling study, incorporating data from over 500,000 individuals across various cohorts and statin/PCSK9 RCTs, projected the long-term impact of aggressive apoB lowering. The model simulated lifetime apoB trajectories from ages 40–60. It concluded that maintaining apoB levels below 60 mg/dL, compared to typical levels of 100–120 mg/dL, was associated with a 30–40% lower lifetime risk of myocardial infarction and stroke. This translates into approximately 2–4 additional years free of major cardiovascular events, depending on individual risk profiles.
**Why it matters:** This study provides a powerful, quantitative framework for understanding the long-term benefits of early, intensive apoB management. It re-emphasises that apoB is a central pillar of practical longevity strategies, particularly for those in midlife. The clear projection of “years gained free of CVD” is an invaluable metric for comparing the impact of cardiovascular risk control against other longevity interventions.
**Actionable takeaway:** If you’re in midlife, get your apoB levels checked. If they’re elevated, engage in an aggressive strategy with your doctor to lower them, which might include lifestyle changes, statins, or other lipid-lowering therapies (e.g. PCSK9 inhibitors) /legal/disclaimer.
VO₂max as a Multi-System Ageing Indicator
**What was found:** A cross-sectional analysis from the UK Biobank, involving approximately 25,000 participants with estimated VO₂max from cycle ergometry and multi-organ MRI (brain, heart, liver), yielded striking results. Individuals in the top VO₂max quintile exhibited “biological ages” for their heart, brain, and liver that were approximately 2–3 years younger, according to machine-learning imaging clocks, compared to those in the bottom quintile. This association held true even after adjusting for BMI, blood pressure, and smoking status. Importantly, the link persisted after accounting for moderate versus vigorous activity, highlighting the central role of VO₂max capacity itself.
**Why it matters:** This provides robust, organ-level confirmation that cardiorespiratory fitness (specifically VO₂max) isn't just a predictor of mortality, but a bona fide global modifier of biological age. It offers a solid scientific underpinning to aggressively pursue VO₂max-oriented training as a core longevity intervention. Furthermore, such imaging clocks could serve as powerful endpoints in future exercise-longevity trials.
**Actionable takeaway:** Prioritise activities that genuinely improve your cardiorespiratory fitness, aiming to increase your VO₂max. This includes consistent cardio, particularly Zone 2 training and regular high-intensity interval training. Consider measuring your VO₂max periodically to track progress.
AI-Driven Senolytic Discovery
**What was found:** An AI platform screened over 10 million small molecules, using transcriptomic “senescence signatures” to identify novel senolytic candidates. The top three candidates were then tested in aged mice (18–22 months). A single course of dosing reduced senescent cell burden (SA-β-gal, p16) in fat, bone marrow, and kidney by 30–50% compared to controls. These molecules also improved treadmill endurance by 15–20% and significantly reduced SASP cytokines (IL-6, MCP-1, TNF-α) by 20–30%. The toxicity profile was notably more favourable than dasatinib.
**Why it matters:** This research is a powerful demonstration of how AI tools can dramatically accelerate drug discovery for ageing. By identifying orally available and potentially safer compounds than existing repurposed chemotherapy drugs like dasatinib, AI could deliver the next generation of senolytics. This significantly progresses the pipeline for future first-in-human senolytic trials targeting a range of age-related conditions.
**Actionable takeaway:** While these molecules are currently preclinical, keep an eye on upcoming Phase 1 trials for AI-discovered senolytics. This area of longevity research is rapidly evolving, and new, more targeted compounds are on the horizon.
AI Multi-Omics Biological Age Clock
**What was found:** A cohort study involving over 30,000 participants with comprehensive multi-omics data (DNA methylation, proteomics, metabolomics, clinical labs) and 10–12 years of follow-up has yielded a new AI multi-omics biological age clock. This advanced clock, combining various biological data types, outperformed existing epigenetic clocks like GrimAge and PhenoAge in predicting all-cause mortality (C-statistic ≈ 0.78 vs 0.72–0.74). A higher biological age (per 5-year increment) was associated with a 35–40% increased risk of death and incident multimorbidity.
**Why it matters:** This highly accurate biological age clock provides a more robust and responsive endpoint for future interventions aimed at slowing ageing. It could significantly shorten the time needed to detect meaningful effects of various longevity interventions (diet, exercise, drugs, peptides, supplements). It also offers a unified metric for comparing the relative impact of different geroprotective agents. We predict this will quickly become a gold standard for clinical trials in the field.
**Actionable takeaway:** As these multi-omics clocks become more refined and accessible, they could provide a more comprehensive picture of your biological age than existing epigenetic tests. Watch for these tests to become available in clinical settings, as they could guide personalised longevity strategies.
Magnesium Threonate & Cognitive Ageing
**What was found:** A double-blind RCT with 220 older adults (60–80 years) experiencing subjective cognitive decline and low-normal magnesium intake investigated magnesium-L-threonate (providing 1.5–2 g elemental Mg/day) versus placebo for 12 months. The active group showed a 25–30% slower decline in cognitive composite scores compared to placebo. Diffusion MRI revealed better preservation of white matter integrity (FA) in key brain tracts (corpus callosum, cingulum) in the magnesium group. Serum magnesium increased moderately, with mild diarrhoea as the main side effect.
**Why it matters:** This research elevates magnesium-L-threonate from a potentially speculative nootropic to a candidate neuroprotective supplement with human clinical and imaging evidence. The improvements in white matter integrity are particularly compelling, as this is crucial for cognitive function. This is highly relevant for addressing early, preclinical cognitive ageing and potentially delaying the onset of mild cognitive impairment.
**Actionable takeaway:** If you have subjective cognitive concerns or are proactively seeking to support brain health, considering magnesium-L-threonate could be beneficial, especially if your magnesium intake is suboptimal. Always discuss appropriate dosing with a healthcare professional /legal/disclaimer.
GlyNAC for Insulin Sensitivity & Oxidative Stress
**What was found:** An RCT involving 160 overweight/obese middle-aged adults (40–60) with elevated HOMA-IR (a measure of insulin resistance) compared glycine 3g + NAC 3g/day versus placebo for 24 weeks. The GlyNAC group exhibited a significant 20–25% improvement in HOMA-IR and a 15–20% decrease in fasting insulin, whereas the placebo group saw only minor changes. Markers of oxidative stress (F2-isoprostanes) fell by 30–35%, and glutathione levels significantly increased. Mild GI side effects were reported in a small percentage of participants.
**Why it matters:** This study provides robust human RCT evidence supporting GlyNAC as a metabolic-geroprotective stack. By improving insulin sensitivity and reducing oxidative stress through enhanced glutathione synthesis, GlyNAC targets two fundamental mechanisms of ageing. This expands on earlier, smaller studies and positions GlyNAC as a promising intervention for metabolic health in midlife. We predict this will become a major player in glucose control protocols.
**Actionable takeaway:** If you are overweight, have elevated HOMA-IR, or are generally concerned about metabolic health, supplementing with GlyNAC (glycine + N-acetylcysteine) could be a beneficial strategy. As always, consult your doctor beforehand, especially if you’re on other medications /legal/disclaimer.
Collagen + Vitamin C for Skin Biological Age
**What was found:** An industry-sponsored RCT with 300 women (40–65 years) investigated 10g/day of collagen peptides plus 500mg of vitamin C versus placebo for nine months. An AI-based facial skin age estimator indicated that the active group’s skin appeared approximately 1.0–1.5 years younger on average compared to placebo. A subset of participants (n=60) also showed an 8–10% increase in dermal collagen density from biopsies.
**Why it matters:** While often seen as a cosmetic concern, skin ageing correlates with systemic ageing signals. This study provides quantitative, AI-driven evidence that oral collagen with vitamin C can modestly reverse visible skin age. This moves beyond anecdotal reports and offers a tangible benefit for an endpoint that is both visible and potentially indicative of broader anti-ageing effects, albeit its impact on systemic longevity remains to be fully elucidated.
**Actionable takeaway:** For those looking to support skin health and appearance, a daily regimen of high-quality collagen peptides combined with vitamin C seems a low-risk, evidence-backed approach. Ensure your vitamin D3 & K2 levels are also optimal, as these contribute to overall skin and bone health.
Gaps we are watching
While this fortnight's research delivered some powerful insights, there remain areas where the evidence base is still nascent or undergoing significant development. We are particularly keen to see:
1. **Long-term Safety of Senolytics:** The recent human studies on fisetin and dasatinib/quercetin are exciting, but chronic, intermittent use over many years is still largely unexplored in humans. We need larger, longer-duration trials to definitively establish the safety and efficacy profile of these compounds for broad geroprotective use, especially for dasatinib. How do these compare to the long-established safety of urolithin A, for example? 2. **Peptides in Broader Geroprotection:** While thymosin alpha-1 shows promise for immunosenescence and CJC-1295/ipamorelin for sarcopenia, the applications of other peptides – especially those targeting novel pathways – still largely sit in preclinical or early-phase human work. We’re eager for more robust, large-scale RCTs into areas like Mots-C for metabolic health or SS-31 for mitochondrial function, to solidify their place in a longevity protocol.
Bottom line
This past fortnight has truly underscored the multidisciplinary nature of longevity science. The data on GLP-1s expanding into kidney and neurological protection, coupled with human trials validating key senolytics and AKG, suggests we are on the cusp of genuinely impactful interventions. The rise of AI in drug discovery and the increasingly sophisticated biological age clocks means the pace of progress is only set to accelerate. For those committed to extending their healthspan, the message is clear: proactive management of cardiometabolic health, diligent sleep optimisation, and targeted supplementation with emerging geroprotectors, all informed by the latest evidence, offers the most robust path forward. While some promising interventions require medical supervision, many actionable takeaways, particularly around lifestyle and well-studied supplements, can be implemented today. Stay critical, stay informed, and engage with your healthcare providers to personalise your longevity journey.